Clinical Trials Logo

Warts clinical trials

View clinical trials related to Warts.

Filter by:

NCT ID: NCT06309420 Completed - Warts Clinical Trials

Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts

Start date: November 7, 2019
Phase: N/A
Study type: Interventional

The present study was set-up to evaluate clinical efficacy of Pixie CO2 versus a comparator product (Wortie®) for the treatment of common and plantar warts.

NCT ID: NCT06281353 Completed - Anogenital Wart Clinical Trials

The Effect of Oral Nanocurcumin as an Adjuvant Therapy for Anogenital Warts: Evaluation of Clinical Improvement, NFĸB, IFN-γ, and FOXP3+TReg From Lesions Tissue

Start date: August 16, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this clinical trial is to demonstrate the adjuvant administration of oral nanocurcumin in 90% TCA therapy that increases the proportion of clinical improvement in patients with Anogenital Warts (AGW), mediated by NFĸB, IFN-γ, and FOXP3+Treg. Specific objectives of this clinical trial include: - To prove that the oral administration of nanocurcumin decreases the levels of IFN-γ, FOXP3+Treg, and NFĸB in lesions of AGW patients, and - To demonstrate that the reduction in IFN-γ, FOXP3+Treg, and NFĸB levels in lesions is associated with the proportion of clinical improvement in AGW patients undergoing TCA 90% therapy with adjuvant of oral nanocurcumin. The main questions it aims to answer are: - Does adjuvant oral nanocurcumin administration in 90% TCA therapy increase the proportion of clinical improvement in patients with AGW compared to controls (90% TCA therapy alone)? - Is there a greater decrease in IFN-γ, FOXP3+Treg, and NFĸB levels in lesions of patients with AGW given adjuvant oral nanocurcumin compared to controls? - Is the decrease in IFN-γ, FOXP3+TReg, and NFĸB levels in lesions of patients with AGW, with adjunctive oral nanocurcumin administration in 90% TCA therapy, associated with the degree of clinical improvement in patients with AGW? Participants will be divided into 2 groups. The first one was given capsules without active ingredients/nanocurcumin (control group), and the second one was given capsules with nanocurcumin (experimental group), both group received a dosage of 200mg capsules per day after breakfast, for 8 weeks. The researchers conducted a comparison between those 2 groups to assess whether the adjuvant administration of oral nanocurcumin in 90% TCA therapy enhances the proportion of clinical improvement in patients with AGW.

NCT ID: NCT06261684 Recruiting - Plantar Wart Clinical Trials

Intralesional Acyclovir Versus Cryotherapy in the Treatment of Plantar Warts. A Randomized Controlled Trial.

Start date: October 1, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

The goal of this prospective randomized controlled study is to study the safety and efficacy of intralesional acyclovir compared to cryotherapy in plantar warts. The main questions needed to be answered are: 1. Is Intralesional acyclovir safe for plantar warts? 2. Is Intralesional acyclovir more efficient in treating plantar warts compared to cryotherapy?

NCT ID: NCT06233019 Completed - Plane Wart Clinical Trials

Glycolic Acid Plus Salicylic Acid in Treatment of Plane Wart

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

To determine clinical efficacy of glycolic acid 15%plus salicylic acid 2% gel in treatment of Plane wart .

NCT ID: NCT06228521 Completed - Warts of Foot Clinical Trials

Efficacy & Safety of 980nm Diode Laser vs. Cryotherapy for Plantar Warts

LAVsCryWarts
Start date: February 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare and test the efficacy of two treatments for plantar warts. The main questions it aims to answer are: Which treatment has a higher cure rate for eliminating plantar warts? Which treatment causes less pain during the procedure? Participants with plantar warts will: Be randomly assigned to receive either cryotherapy or laser therapy Undergo 4 treatment sessions at weekly intervals Have their warts assessed for complete clearance after treatment Rate their pain levels during each session Researchers will compare the cryotherapy and laser therapy groups to see if there are differences in: Rates of complete wart clearance Pain levels reported during treatment Adverse effects

NCT ID: NCT06214559 Recruiting - Warts Clinical Trials

Evaluate the Effectiveness and the Safety of a Medical Device in the Treatment of Common Warts and Plantar Warts.

Start date: February 19, 2024
Phase: N/A
Study type: Interventional

The principal aim of this study is to evaluate the efficacy and the safety of the tested product on common and plantar wart after 35 days of treatment. For this study, 33 patients presenting at least one common wart on the fingers, back on the hand or a plantar wart of a size between 0.1 and 0.5cm and present since less than 6 months will be included to reach this objective

NCT ID: NCT06077032 Not yet recruiting - Non-Genital Warts Clinical Trials

Chlorhexidine and Garlic Extract as Potential Topical Virucidal Therapeutic Agents of Non-Genital Warts

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

Aim(s) of the Research: 1. Evaluate the efficacy and safety of topical chlorhexidine (2%) solution vs garlic extract (15%) solution in treating non-genital warts. 2. Explore possible relation between therapeutic response with demographic/clinical data. 3. Identify patients satisfaction with each agent.

NCT ID: NCT05937672 Recruiting - Clinical trials for Molluscum Contagiosum

Cold Atmospheric Plasma Device Extension Study

Start date: September 18, 2023
Phase: Phase 3
Study type: Interventional

Patients between 4-21 years of age with at least one wart or molluscum lesion are eligible to participate in this study. The duration of the study is a minimum of 4 weeks with the maximum duration of monthly treatments for one year, depending on lesion clearance. The number of lesions will be chosen by the dermatologist. Patients who opt to participate will receive non-thermal, or cold, atmospheric plasma to treat all lesions selected. Safety profile as well as changes in size, pain and appearance will be measured. Photographs and dermatologist impressions will be used to measure treatment response.

NCT ID: NCT05902624 Not yet recruiting - Cutaneous Warts Clinical Trials

Efficacy and Safety of Hepatitis B Virus Vaccine(HBV) in Treatment of Cutaneous Warts

Start date: June 10, 2023
Phase: Early Phase 1
Study type: Interventional

Aim of the work: 1. Evaluate efficacy and safety of Intralesional HBV vaccine injection as a treatment of plane and genital warts. 2. Evaluate efficacy and safety of Intramuscular HBV vaccine injection as a treatment of plane and genital warts. 3. Compare the efficacy of different doses(0.3ml vs 0.5ml )of intralesional HBV vaccine injection for treatment of plane and genital warts. 4. Compare the efficacy of intralesional HBV vaccine injection vs Intramuscular HBV vaccine injection in treatment of plane and genital warts.

NCT ID: NCT05896215 Active, not recruiting - Common Wart Clinical Trials

OM202JP Clinical Study of KNP2002

Start date: June 12, 2023
Phase: Phase 2
Study type: Interventional

The goal of this clinical trial is to evaluate safety and efficacy of KNP2002 in patients with common warts aged 15 to 50 years old.